Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC 683864, IND 61010) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma.

Trial Profile

Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC 683864, IND 61010) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Temsirolimus (Primary) ; Megestrol; Tamoxifen
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 02 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jan 2017.
    • 27 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top